Patent · US Active

Solid forms of a Raf kinase inhibitor

US8324389B2 · kind B2 · utility

1Cited by

2References

9Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Ahmad Hashash · Cambridge, US
Kangwen L. Lin · Fremont, US
Augustus O. Okhamafe · Concord, US

Key dates

Filing date	Feb 28, 2008
Grant date	Dec 4, 2012
Priority date	—
Expiry date	Jun 18, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.